Predictors of pain perception and quality of life in a 1-year follow-up of patients with Chronic pelvic pain syndrome (CPPS)

Background: Chronic prostatitis/chronic pelvic pain syndrome (IIIB CP/CPPS) is a condition of unclear aetiology. Many approaches have been used without satisfactory results. The aim of this study is to evaluate the efficacy of once-daily 5 mg tadalafil in pain control and improving quality of life in patients affected by CP/CPPS. Methods: Twenty patients affected by chronic prostatitis according EAU (European Association of Urology) guidelines were evaluated for once-daily 5 mg tadalafil; 14 patients were eligible for the study. The validated Italian version of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the International Prostatic Symptom Score (IPSS) questionnaires were submitted to all the patients. Every patient underwent uroflowmetry and ultrasound prostatic volume at the beginning and at the end of the study. Results: All 14 patients eligible for the study reported an improvement of symptoms during therapy: statistically significant differences were reported in terms of NIH-CPSI ( p < 0.000002) and IPSS ( p < 0.0001) during follow-up evaluations. No statistically significant improvement of uroflowmetry parameters was reported during the treatment. Conclusions: In our study the daily use of 5 mg tadalafil improves symptoms and quality of life in patients affected by CP/CPPS after 4 weeks of therapy. A larger population of patients is needed to confirm the efficacy of this therapy in CP/CPPS.

Download Full-text

Chronic Pelvic Pain: Assessment, Evaluation, and Objectivation

Pain Research and Treatment ◽

10.1155/2017/9472925 ◽

2017 ◽

Vol 2017 ◽

pp. 1-15 ◽

Cited By ~ 5

Author(s):

Maria Beatrice Passavanti ◽

Vincenzo Pota ◽

Pasquale Sansone ◽

Caterina Aurilio ◽

Lorenzo De Nardis ◽

...

Keyword(s):

Quality Of Life ◽

Pelvic Pain ◽

Pain Assessment ◽

Chronic Pelvic Pain ◽

Chronic Pelvic Pain Syndrome ◽

Pain Syndrome ◽

Pelvic Pain Syndrome ◽

Men And Women

Chronic Pelvic Pain (CPP) and Chronic Pelvic Pain Syndrome (CPPS) have a significant impact on men and women of reproductive and nonreproductive age, with a considerable burden on overall quality of life (QoL) and on psychological, functional, and behavioural status. Moreover, diagnostic and therapeutic difficulties are remarkable features in many patients. Therefore evaluation, assessment and objectivation tools are often necessary to properly address each patient and consequently his/her clinical needs. Here we review the different tools for pain assessment, evaluation, and objectivation; specific features regarding CPP/CPPS will be highlighted. Also, recent findings disclosed with neuroimaging investigations will be reviewed as they provide new insights into CPP/CPPS pathophysiology and may serve as a tool for CPP assessment and objectivation.

Download Full-text

Uretharal syndrome in men-chronic pelvic pain syndrome

Acta chirurgica iugoslavica ◽

10.2298/aci0901081c ◽

2009 ◽

Vol 56 (1) ◽

pp. 81-89 ◽

Cited By ~ 1

Author(s):

B.R. Cvetkovic ◽

Z.P. Cvetkovic ◽

D. Milenkovic ◽

A. Adamovic

Keyword(s):

Quality Of Life ◽

Pelvic Pain ◽

Significant Influence ◽

Chronic Pelvic Pain ◽

Chronic Pelvic Pain Syndrome ◽

Pain Syndrome ◽

Pelvic Pain Syndrome ◽

Symptom Index ◽

Pain Symptoms

Introduction: Chronic pelvic pain syndrome (CPPS) is defined as pelvis minor pain of nonmalignant nature repeating in different time intervals. Urethral syndrome (US) represents a most poorly defined entity within CPPS. Objective: The estimation of US influence on quality of-life as well as the determination of the way of treatment and therapy optimal length. Material and methods: A prospective one-year study included 166 men with CPPS, median age of 54 years; they were monitored clinically. During the patient monitoring the NIH-CPSI questionnaire (National Institute of Health- Chronic Prostatis Symptom Index) was used. US was diagnosed in 79 patients (47%), and according to the most intensive pain localization they were divided into three groups. All the patients were treated with alpha adrenergic blockers and non-steroidal anti-inflammatory drugs, and the treatment of the patients with positive urethral smear also included antibiotherapy. The values of total NIHCPSI, as well as of its individual components were analyzed after three and six months of treatment. Results and discussion: The therapy application had a significant influence on the decrease of total NIH-CPSI - 23.3% (p<0,01), pain symptoms (p<0.0) and urinary difficulties (p<0.01), and the point values of quality-of-life score were diminished by 0.7 to 1.9 points depending on the group of those monitored (p<0.01). Conclusion: Our study indicated a significant influence of CPPS on quality-of-life and a necessity of a serious approach to patients and their treatment.

Download Full-text